An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell transplants in multiple myeloma, ceases enrollment earlier, based on positive interim data. Trial enrollment is now complete at 122 participants, while the original target was 177, according to a press release by BioLineRx, the therapy’s maker. Full results of the study will be announced after the last patient completes 100 days of…
You must be logged in to read/download the full post.
The post No More Patients Needed in GENESIS Trial of Motixafortide, Committee Says appeared first on BioNewsFeeds.